Gabelli & CO Investment Advisers, Inc. Cerevel Therapeutics Holdings, Inc. Transaction History

Gabelli & CO Investment Advisers, Inc.

  • $535 Million
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024
SELL
$38.96 - $42.75 $11 Million - $12.1 Million
-283,350 Reduced 63.29%
164,345 $6.72 Million
Q1 2024

May 14, 2024
BUY
$40.88 - $43.27 $7.04 Million - $7.45 Million
172,195 Added 62.5%
447,695 $18.9 Million
Q4 2023

Feb 13, 2024
BUY
$20.27 - $42.44 $5.58 Million - $11.7 Million
275,500 New
275,500 $11.7 Million

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Gabelli & CO Investment Advisers, Inc. Portfolio

Follow Gabelli & CO Investment Advisers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gabelli & CO Investment Advisers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gabelli & CO Investment Advisers, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email